|
gptkbp:instanceOf
|
gptkb:person
|
|
gptkbp:almaMater
|
gptkb:University_of_Cambridge
|
|
gptkbp:children
|
2
|
|
gptkbp:dateOfBirth
|
1957-11-11
|
|
gptkbp:dateOfDeath
|
2020-10-26
|
|
gptkbp:doctoralAdvisor
|
gptkb:James_Staunton
|
|
gptkbp:educatedAt
|
gptkb:University_of_Cambridge
|
|
gptkbp:employer
|
gptkb:University_of_Cambridge
|
|
gptkbp:fellowOf
|
gptkb:Academy_of_Medical_Sciences
gptkb:Royal_Society
gptkb:Royal_Society_of_Chemistry
|
|
gptkbp:fieldOfWork
|
chemical biology
microfluidics
fragment-based drug discovery
|
|
gptkbp:founder
|
gptkb:Aqdot
gptkb:Sphere_Fluidics
gptkb:Astex_Therapeutics
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Christopher Abell
|
|
gptkbp:memberOf
|
gptkb:Department_of_Chemistry,_University_of_Cambridge
|
|
gptkbp:nationality
|
British
|
|
gptkbp:occupation
|
gptkb:academic
biological chemist
|
|
gptkbp:positionHeld
|
Professor of Biological Chemistry
|
|
gptkbp:spouse
|
gptkb:Mary_Abell
|
|
gptkbp:thesisTitle
|
Biosynthesis of the macrolide antibiotic erythromycin
|
|
gptkbp:thesisYear
|
1982
|
|
gptkbp:bfsParent
|
gptkb:Chris_Abell
|
|
gptkbp:bfsLayer
|
6
|